Myriad’s myPath® Melanoma Test Receives Medicare Coverage
Go back to Myriad’s myPath® Melanoma Test Receives Medicare Coverage| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 3.02 +0.15 (5.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.87 | 52 Week High | $45.34 | |||
| Open | $2.95 | 52 Week Low | $15.92 | |||
| Day High | $3.03 | P/E | 1.30 | |||
| Day Low | $2.92 | EPS | $2.33 | |||
| Volume | 201,638 | |||||
